Related references
Note: Only part of the references are listed.Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron
Tomáš Šimůnek et al.
Pharmacological Reports (2014)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Dexrazoxane provided moderate protection in a catecholamine model of severe cardiotoxicity
Libuse Zatloukalova et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2012)
Daunorubicin therapy is associated with upregulation of E3 ubiquitin ligases in the heart
Balindiwe J. N. Sishi et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2012)
Anthracycline cardiotoxicity
Pierantonio Menna et al.
EXPERT OPINION ON DRUG SAFETY (2012)
Cardiac phosphoproteome reveals cell signaling events involved in doxorubicin cardiotoxicity
Severine Gratia et al.
JOURNAL OF PROTEOMICS (2012)
Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients
Heloisa Sawaya et al.
AMERICAN JOURNAL OF CARDIOLOGY (2011)
Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials
Fausto Petrelli et al.
ANTI-CANCER DRUGS (2011)
In vivo and in vitro assessment of the role of glutathione antioxidant system in anthracycline-induced cardiotoxicity
Anna Vavrova et al.
ARCHIVES OF TOXICOLOGY (2011)
NADPH oxidases in cardiovascular disease: insights from in vivo models and clinical studies
Alexander Sirker et al.
BASIC RESEARCH IN CARDIOLOGY (2011)
Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats
El-Sayed M. Ammar et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2011)
The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats
V. Ashutosh Rao et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Targeting the Mitochondrial Permeability Transition: Cardiac Ischemia-Reperfusion Versus Carcinogenesis
Sabzali Javadov et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2011)
The use of liposomal anthracycline analogues for childhood malignancies: A systematic review
E. Sieswerda et al.
EUROPEAN JOURNAL OF CANCER (2011)
Cardioprotective effect of dexrazoxane in a rat model of myocardial infarction: Anti-apoptosis and promoting angiogenesis
Ligang Zhou et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2011)
Proteomic insights into chronic anthracycline cardiotoxicity
Martin Sterba et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2011)
Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity
Pavlina Haskova et al.
TOXICOLOGY (2011)
Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented?
Ronald M. Witteles et al.
HEART FAILURE CLINICS (2011)
Reduced in vivo high-energy phosphates precede Adriamycin-induced cardiac dysfunction
M. Y. Maslov et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2010)
Nox2 NADPH Oxidase Promotes Pathologic Cardiac Remodeling Associated with Doxorubicin Chemotherapy
Youyou Zhao et al.
CANCER RESEARCH (2010)
Comparison of Clinically Used and Experimental Iron Chelators for Protection against Oxidative Stress-Induced Cellular Injury
Petra Bendova et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2010)
Mechanisms of Anthracycline Cardiotoxicity and Strategies to Decrease Cardiac Damage
Carrie Anna Geisberg et al.
CURRENT HYPERTENSION REPORTS (2010)
Scavenging Effects of Dexrazoxane on Free Radicals
Zhang Junjing et al.
JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION (2010)
The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: An EPR study
Patric J. Jansson et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2010)
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial
Steven E. Lipshultz et al.
LANCET ONCOLOGY (2010)
Cardiotoxicity of anticancer treatments: what the cardiologist needs to know
Michael S. Ewer et al.
NATURE REVIEWS CARDIOLOGY (2010)
Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy
Rui A. Carvalho et al.
TOXICOLOGY (2010)
Can Anthracycline Therapy for Pediatric Malignancies Be Less Cardiotoxic?
Joy M. Fulbright et al.
CURRENT ONCOLOGY REPORTS (2010)
Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil
Rabaa M. Al-Rousan et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro
Partha Mukhopadhyay et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2009)
How mitochondria produce reactive oxygen species
Michael P. Murphy
BIOCHEMICAL JOURNAL (2009)
Improving the therapeutic index of anthracycline chemotherapy: Focus on liposomal doxorubicin (Myocet™)
R. C. F. Leonard et al.
BREAST (2009)
Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death
O. Popelova et al.
BRITISH JOURNAL OF CANCER (2009)
Respiratory chain deficiency precedes the disrupted calcium homeostasis in chronic doxorubicin cardiomyopathy
Dirk Lebrecht et al.
CARDIOVASCULAR PATHOLOGY (2009)
The Novel Iron Chelator, 2-Pyridylcarboxaldehyde 2-Thiophenecarboxyl Hydrazone, Reduces Catecholamine-Mediated Myocardial Toxicity
Premysl Mladenka et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2009)
American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants
Martee L. Hensley et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The iron chelator Dp44mT does not protect myocytes against doxorubicin
Brian B. Hasinoff et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2009)
Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase Inhibitors
Yu Yu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Differential roles of nitric oxide synthase isozymes in cardiotoxicity and mortality following chronic doxorubicin treatment in mice
Shiwei Deng et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2009)
Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy
Elke Martin et al.
TOXICOLOGY (2009)
Iron Chelation Protects the Retinal Pigment Epithelial Cell Line ARPE-19 against Cell Death Triggered by Diverse Stimuli
Nina Lukinova et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2009)
Glutathione peroxidase 1-deficient mice are more susceptible to doxorubicin-induced cardiotoxicity
Jinping Gao et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2008)
Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone
T. Simunek et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Cardiotoxicity of antitumor drugs
Pierantonio Menna et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2008)
Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as protectants, against anthracycline-induced cardiotoxicity
Tomas Simunek et al.
HEMOGLOBIN (2008)
Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane
Elly V. Barry et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Anthracycline cardiotoxicity: From bench to bedside
Luca Gianni et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Iron prochelator BSIH protects retinal pigment epithelial cells against cell death induced by hydrogen peroxide
Louise K. Charkoudian et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2008)
Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells
Francisco Molina-Holgado et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Investigation of the stability of aromatic hydrazones in plasma and related biological material
Petra Kovarikova et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2008)
Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo
Olga Popelova et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class
C. K. Lim et al.
MOLECULAR PHARMACOLOGY (2008)
THE ROLE OF BIOMARKERS IN THE EARLY DETECTION OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN CHILDREN: A Review of the Literature
Annelies M. C. Mavinkurve-Groothuis et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2008)
Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study
Mark Hackbarth et al.
SUPPORTIVE CARE IN CANCER (2008)
The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study
A. M. E. Bruynzeel et al.
BRITISH JOURNAL OF CANCER (2007)
Topoisomerase IIβ-Mediated DNA double-strand breaks:: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane
Yi Lisa Lyu et al.
CANCER RESEARCH (2007)
Long-term effects of 7-monohydroxyethylrutoside (monoHER) on DOX-induced cardiotoxicity in mice
Anna M. E. Bruynzeel et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors
Melissa M. Hudson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats
D. Lebrecht et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Potentiation of doxorubicin cardiotoxicity by iron loading in a rodent model
Gurusher S. Panjrath et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity:: A study of salicylaldehyde isonicotinoyl hydrazone (SIH)
Martin Sterba et al.
TOXICOLOGY (2007)
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management
Elly Barry et al.
EXPERT OPINION ON PHARMACOTHERAPY (2007)
Dexrazoxane-Associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease
Cameron K. Tebbi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Molecular and cellular mechanisms of anthracycline cardiotoxicity
Billy Chen et al.
CARDIOVASCULAR TOXICOLOGY (2007)
Adriamycin-induced oxidative mitochondrial cardiotoxicity
J. M. Berthiaume et al.
CELL BIOLOGY AND TOXICOLOGY (2007)
Persistent alterations to the gene expression profile of the heart subsequent to chronic doxorubicin treatment
Jessica M. Berthiaume et al.
CARDIOVASCULAR TOXICOLOGY (2007)
Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: insight into the mechanism of chemobrain
Jitbanjong Tangpong et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Pathophysiology and diagnosis of cancer drug induced cardiomyopathy
Christian Zuppinger et al.
CARDIOVASCULAR TOXICOLOGY (2007)
Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis
Kendall B. Wallace
CARDIOVASCULAR TOXICOLOGY (2007)
Anthracycline cardiotoxicity in long-term survivors of childhood cancer
Rebecca E. Scully et al.
CARDIOVASCULAR TOXICOLOGY (2007)
Long-term and short-term models for studying anthracycline cardiotoxicity and protectors
Jacques Robert
CARDIOVASCULAR TOXICOLOGY (2007)
An introduction to the metabolic determinants of anthracycline cardiotoxicity
Pierantonio Menna et al.
CARDIOVASCULAR TOXICOLOGY (2007)
Role of mtDNA lesions in anthracycline cardiotoxicity
Dirk Lebrecht et al.
CARDIOVASCULAR TOXICOLOGY (2007)
Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes
Luca Gianni et al.
CARDIOVASCULAR TOXICOLOGY (2007)
Genotyping the risk of anthracycline-induced cardiotoxicity
Shiwei Deng et al.
CARDIOVASCULAR TOXICOLOGY (2007)
Protective effects of carvedilol against anthracycline-induced cardiomyopathy
Nihat Kalay et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity
Martin Sterba et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Cardioprotective effects of subcutaneous ebselen against daunorubicin-induced cardiomyopathy in rats
Sherif Y. Saad et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2006)
Anthracycline cardiotoxicity
Robin L. Jones et al.
EXPERT OPINION ON DRUG SAFETY (2006)
Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences
Hava Glickstein et al.
BLOOD (2006)
A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics
Megan Whitnall et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Caged-iron chelators a novel approach towards protecting skin cells against UVA-induced necrotic cell death
Anthie Yiakouvaki et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin
Ling-Jie Xu et al.
ACTA PHARMACOLOGICA SINICA (2006)
Dexrazoxane prevents myocardial ischemia/reperfusion-induced oxidative stress in the rat heart
Eyal Ramu et al.
CARDIOVASCULAR DRUGS AND THERAPY (2006)
A pro-chelator triggered by hydrogen peroxide inhibits iron-promoted hydroxyl radical formation
Louise K. Charkoudian et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2006)
HPLC determination of a novel aroylhydrazone iron chelator (o-108) in rabbit plasma and its application to a pilot pharmacokinetic study
Petra Kovarikova et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2006)
Attenuation of doxorubicin-induced contractile and mitochondrial dysfunction in mouse heart by cellular glutathione peroxidase
Ye Xiong et al.
FREE RADICAL BIOLOGY AND MEDICINE (2006)
Intralysosomal iron chelation protects against oxidative stress-induced cellular damage
Tino Kurz et al.
FEBS JOURNAL (2006)
Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane®) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy
M Marty et al.
ANNALS OF ONCOLOGY (2006)
Depletion of adenine nucleotide translocator protein in heart mitochondria from doxorubicin-treated rats- Relevance for mitochondrial. dysfunction
PJ Oliveira et al.
TOXICOLOGY (2006)
Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up
L Elbl et al.
SUPPORTIVE CARE IN CANCER (2006)
New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics
Malgorzata Tokarska-Schlattner et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2006)
The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity
MP Cole et al.
CARDIOVASCULAR RESEARCH (2006)
NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity
L Wojnowski et al.
CIRCULATION (2005)
Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies
KA Wouters et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin
D Lebrecht et al.
JOURNAL OF PATHOLOGY (2005)
The evolution of iron chelators for the treatment of iron overload disease and cancer
DS Kalinowski et al.
PHARMACOLOGICAL REVIEWS (2005)
Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients
L Elbl et al.
EUROPEAN JOURNAL OF PEDIATRICS (2005)
Inhibitory effects of rosmarinic acid on adriamycin-induced apoptosis in H9c2 cardiac muscle cells by inhibiting reactive oxygen species and the activations of c-Jun N-terminal kinase and extracellular signal-regulated kinase
DS Kim et al.
BIOCHEMICAL PHARMACOLOGY (2005)
SIH -: a novel lipophilic iron chelator -: protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death
T Simunek et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2005)
Development of high-performance liquid chromatographic determination of salicylaldehyde isonicotinoyl hydrazone in rabbit plasma and application of this method to an in vivo study
P Kovaríková et al.
JOURNAL OF SEPARATION SCIENCE (2005)
Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply
M Tokarska-Schlattner et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2005)
Manganese superoxide dismutase and inducible nitric oxide synthase modify early oxidative events in acute Adriamycin-induced mitochondrial toxicity
L Chaiswing et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Pathophysiology of anthracycline- and radiation-associated card iomyopathies: Implications for screening and prevention
MJ Adams et al.
PEDIATRIC BLOOD & CANCER (2005)
Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood
PE Schroeder et al.
DRUG METABOLISM AND DISPOSITION (2005)
Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits
T Simunek et al.
BIOMETALS (2005)
Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits
T Simünek et al.
PHARMACOLOGICAL RESEARCH (2005)
Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction
JM Berthiaume et al.
CARDIOVASCULAR TOXICOLOGY (2005)
The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of ironmediated reactive oxygen species
X Wu et al.
ANTI-CANCER DRUGS (2005)
Dexrazoxane - A review of its use for cardioprotection during anthracycline chemotherapy
RS Cvetkokic et al.
DRUGS (2005)
Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat
PE Schroeder et al.
DRUG METABOLISM AND DISPOSITION (2005)
The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage
S Fogli et al.
FASEB JOURNAL (2004)
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
MER O'Brien et al.
ANNALS OF ONCOLOGY (2004)
Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes
CC Lim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Does anthracycline administration by infusion in children affect late cardiotoxicity?
GA Levitt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis
D Lebrecht et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2004)
The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia
SE Lipshultz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents
T Simunek et al.
EUROPEAN JOURNAL OF HEART FAILURE (2004)
Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
G Minotti et al.
PHARMACOLOGICAL REVIEWS (2004)
Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity
PJ Oliveira et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2004)
The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review
SM Swain et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2004)
The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin
BB Hasinoff et al.
FREE RADICAL BIOLOGY AND MEDICINE (2003)
Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy
D Lebrecht et al.
CIRCULATION (2003)
New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity
E El-Demerdash et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2003)
Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin
CJ Miranda et al.
BLOOD (2003)
Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187
S Classen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Doxorubicin-induced cardiac mitochondrionopathy
KB Wallace
PHARMACOLOGY & TOXICOLOGY (2003)
The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity
BB Hasinoff et al.
MOLECULAR PHARMACOLOGY (2003)
Characterization of p53-mediated up-regulation of CD95 gene expression upon genotoxic treatment in human breast tumor cells
C Ruiz-Ruiz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide
PE Schroeder et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2003)
Dexrazoxane does not protect against doxorubicin-induced damage in young rats
S Héon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2003)
Role of deferiprone in chelation therapy for transfusional iron overload
AV Hoffbrand et al.
BLOOD (2003)
Congestive heart failure in patients treated with doxorubicin - A retrospective analysis of three trials
SM Swain et al.
CANCER (2003)
Mitochondrials complex I activity is reduced in latent adriamycin-induced cardiomyopathy of rat
K Ohkura et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2003)
Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: Inhibition of the ferritin iron mobilization pathway
JC Kwok et al.
MOLECULAR PHARMACOLOGY (2003)
Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction
P Pacher et al.
CIRCULATION (2003)
Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy
DL Santos et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2002)
The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925
PE Schroeder et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Comparative study of chronic toxic effects of daunorubicin and doxorubicin in rabbits
I Klimtová et al.
HUMAN & EXPERIMENTAL TOXICOLOGY (2002)
Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group
TA O'Brien et al.
BLOOD (2002)
Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: The iron and copper complexes of anthracyclines decrease RNA-binding activity
JC Kwok et al.
MOLECULAR PHARMACOLOGY (2002)
Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia
X Thomas et al.
ANNALS OF HEMATOLOGY (2002)
Deferiprone protects against doxorubicin-induced myocyte cytotoxicity
N Barnabé et al.
FREE RADICAL BIOLOGY AND MEDICINE (2002)
Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients
BV Jensen et al.
ANNALS OF ONCOLOGY (2002)
Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics
EL de Beer et al.
BRITISH JOURNAL OF PHARMACOLOGY (2002)
Doxorubicin administration by continuous infusion is not cardioprotective: The Dana-Farber 91-01 acute lymphoblastic leukemia protocol
SE Lipshultz et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Iron deficiency and iron excess damage mitochondria and mitochondrial DNA in rats
PB Walter et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Multiple interference of anthracyclines with mitochondrial creatine kinases: Preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity
M Tokarska-Schlattner et al.
MOLECULAR PHARMACOLOGY (2002)
Melatonin protects against cardiac toxicity of doxorubicin in rat
MF Xu et al.
JOURNAL OF PINEAL RESEARCH (2001)
In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy:: time to consider expanded clinical trials?
DR Budman et al.
LEUKEMIA (2001)
The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin and mitoxantrone-induced cardiotoxicity
EH Herman et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2001)
Propionyl-L-carnitine as protector against adriamycin-induced cardiomyopathy
MM Sayed-Ahmed et al.
PHARMACOLOGICAL RESEARCH (2001)
The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats
SY Saad et al.
PHARMACOLOGICAL RESEARCH (2001)
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer
G Batist et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice
SW Langer et al.
ANNALS OF ONCOLOGY (2001)
Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol
TM Li et al.
CIRCULATION (2000)
Prevention by dexrazoxane of down-regulation of ryanodine receptor gene expression in anthracycline cardiomyopathy in the rat
BE Burke et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
The antioxidant effects of a novel iron chelator salicylaldehyde isonicotinoyl hydrazone in the prevention of H2O2 injury in adult cardiomyocytes
M Horackova et al.
CARDIOVASCULAR RESEARCH (2000)
Apoptosis in rat cardiac myocytes induced by Fas ligand: Priming for Fas-mediated apoptosis with doxorubicin
M Yamaoka et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2000)
Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats
TM Li et al.
CARDIOVASCULAR RESEARCH (2000)
Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases
YJ Kang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy.
GM Felker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats
EH Herman et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)
Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics, and DNA cleavage activity
NK Diop et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2000)
Share Paper
